Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple

Deutsche Bank backs AtaiBeckley in the Psychedelic Renaissance, citing drugs BPL-003, VLS-01 and EMP-01 and projecting multibillion dollar sales after FDA approval.

Leave a Reply

Your email address will not be published. Required fields are marked *